4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors

A compound having the structure of formula I:

• or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein:
• X is halo;
• Ak is C1-6 alkyl optionally substituted with one or more fluorine atoms;
• s is 1 or 2;
• L is C(O), S(O)2, CH2, or a bond;
• Q is a 6-membered heteroaromatic ring containing 1, 2 or 3 N atoms;
• R1 is R3;
• R2 is H, methyl, or R3;
• or R1 and R2, together with the N-atom to which they are attached, form a 4- to 7-membered heterocyclic group that is fully saturated or partially unsaturated, which heterocyclic group contains one N atom, and wherein the heterocyclic group
• (a) further contains one S atom and is optionally substituted with one or more halo, hydroxy, oxo, C1-4 alkyl, C1-4 alkoxy, or C1-4 hydroxyalkyl;
• or
• (b) optionally contains one or more further heteroatoms selected from N, O and S, is substituted with one or more C1-4 hydroxyalkyl, C1-4 carboxyalkyl, or (C1-4 alkylene)-NRaRb, and is optionally further substituted by one or more substituents selected from halo, hydroxy, oxo, CO2H, C1-4 alkyl and C1-4 alkoxy;
• or
• (c) is fused to a fully saturated or partially unsaturated 5- or 6-membered heterocyclic ring, which 5- or 6-membered heterocylic ring contains one or more heteroatoms selected from N, O and S and is optionally substituted with one or more oxo or C1-4 alkyl;
• R3 is Hetx or C1-6 alkyl,
• wherein the C1-6 alkyl is substituted by one or more —CO2H, —(OCH2CH2)0-4ORc, Hety, Hetz, —NRdC(O)Re, or —S(O)1-2Rf and is optionally further substituted by one or more halo, hydroxyl, or oxo;
• Ra and Rb are each, independently, H or C1-4 alkyl, or Ra and Rb, together with the N-atom to which they are attached, form a 4- to 7-membered heterocyclic group that is fully saturated, partially unsaturated or fully aromatic and which heterocyclic group contains one N atom and, optionally, one or more further heteroatoms selected from O, S and N, and which heterocyclic group is optionally substituted with one or more halo, hydroxy, oxo, C1-4 alkyl, C1-4 alkoxy, or C1-4 hydroxyalkyl;
• Rc, Rd and Re are each, independently, H or C1-4 alkyl,
• Rf is C1-6 alkyl or C3-7 cycloalkyl;
• Hetx is at each occurrence, independently, a 4- to 7-membered heterocyclic group that is fully saturated, partially unsaturated or fully aromatic, which group contains one or more heteroatoms selected from N, O and S, and which group is optionally substituted by one or more C1-4 alkyl, halo, hydroxyl, or oxo;
• Hety is at each occurrence, independently, a 5- to 10-membered heterocyclic group that is fully aromatic, which group contains one or more heteroatoms selected from N, O and S, and which group is optionally substituted by one or more substituents selected from C1-4 alkyl, halo, hydroxy and oxo;
• and
• Hetz is at each occurrence, independently, a 4- to 7-membered heterocyclic group that is fully saturated or partially unsaturated, which group contains one or more heteroatoms selected from N, O and S, and which group is substituted by oxo or hydroxy, and which group is optionally further substituted by one or more substituents selected from C1-4 alkyl, halo, hydroxy and oxo.